Ruthenium complex delivery using liposomes to improve bioactivity against HeLa cells via the mitochondrial pathway. (20th November 2018)

• Record Type: Journal Article
• Authors: Guo, Bohong; Liao, Cancheng; Fang, Yuqi; Li, Shuqi; Li, Xiaofang; Lu, Zhufen; Chen, Yanzhong
• Is Part Of: Nanomedicine. Volume 13:Number 22(2018)
• Page Start: 2851
• Page End: 2866
• Publication Date: 2018-11-20
• Subjects: anticancer activity -- apoptosis -- liposomes -- mitochondria -- ruthenium complex; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2018-0236
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: The aim of this study was to encapsulate a ruthenium complex [Ru(ttbpy)2 PIP](ClO4 )2 (Ru) in liposomes to enhance their antitumor effect on human cervical cancer.Methods: The Ru-loaded PEGylated liposomes (Ru–Lip) were prepared using thin-film hydration method. The mechanism of action was studied.Results: A novel Ru was successfully synthesized. Ru–Lip showed stronger cytotoxic activity against HeLa cells than Ru. Ru–Lip demonstrated a more significant increase in apoptosis, reactive oxygen species production and apoptosis-associated processes (intracellular calcium concentration, cytochrome c release and activation of Bax and caspase-3) than Ru. Ru–Lip exhibited greater blockade efficacy in the cell cycle G1 phase and greater DNA damage than Ru.Conclusion: Ru–Lip significantly elevates the anticancer effect via reactive oxygen species-mediated mitochondrial dysfunctional pathway.